Insights - Amarin released detailed REDUCE-IT data this past Saturday and results were mixed. Although the Vascepa active arm showed strong data, the placebo arm used mineral oil, which … Continue Reading
Read nowInsights - Oncosec (ONCS) reported data from PICES combination trial with Keytruda this morning and came below expectations. ONCS stock is down more than 50% on the data, which … Continue Reading
Read nowInsights - Bellus is expected to report Phase 1 data, which will include taste, sometime in late November – early December. Below we analyze Merck’s Phase 2b … Continue Reading
Read nowInsights - Amarin (AMRN) will present data from their cardiovascular (CV) outcome REDUCE-IT trial on November 10. This data caused AMRN shares to jump from $3 – … Continue Reading
Read nowInsights - ONCS has two ipcoming catalysts with PICES data in November for metastatic melanoma and OMS-140 data for TNBC in December. Prior data (discussed below) leads … Continue Reading
Read nowInsights - Selecta released an 8-K after market today which disclosed that one of the patients in the SEL-403 trial died from a Grade 5 Serious Adverse … Continue Reading
Read nowInsights - Menlo (MNLO), a company developing serlopitant for chronic cough candidate, reported disappointing Phase 2 data. In 185 patients, serlopitant group had 31% less reduction than the placebo group. In … Continue Reading
Read now
